GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Gross Margin %

Waverley Pharma (TSXV:WAVE) Gross Margin % : -100.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Waverley Pharma's Gross Profit for the three months ended in Dec. 2023 was C$-0.05 Mil. Waverley Pharma's Revenue for the three months ended in Dec. 2023 was C$0.05 Mil. Therefore, Waverley Pharma's Gross Margin % for the quarter that ended in Dec. 2023 was -100.00%.


The historical rank and industry rank for Waverley Pharma's Gross Margin % or its related term are showing as below:

TSXV:WAVE' s Gross Margin % Range Over the Past 10 Years
Min: 4.24   Med: 14.02   Max: 22.77
Current: 19.37


During the past 8 years, the highest Gross Margin % of Waverley Pharma was 22.77%. The lowest was 4.24%. And the median was 14.02%.

TSXV:WAVE's Gross Margin % is ranked worse than
84.72% of 746 companies
in the Biotechnology industry
Industry Median: 59.74 vs TSXV:WAVE: 19.37

Waverley Pharma had a gross margin of -100.00% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Waverley Pharma was 19.90% per year.


Waverley Pharma Gross Margin % Historical Data

The historical data trend for Waverley Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Gross Margin % Chart

Waverley Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 4.24 13.24 12.72 22.77 19.42

Waverley Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.44 1.68 68.46 26.04 -100.00

Competitive Comparison of Waverley Pharma's Gross Margin %

For the Biotechnology subindustry, Waverley Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waverley Pharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's Gross Margin % falls into.



Waverley Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Waverley Pharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0.1 / 0.412
=(Revenue - Cost of Goods Sold) / Revenue
=(0.412 - 0.332) / 0.412
=19.42 %

Waverley Pharma's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0 / 0.049
=(Revenue - Cost of Goods Sold) / Revenue
=(0.049 - 0.098) / 0.049
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Waverley Pharma  (TSXV:WAVE) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Waverley Pharma had a gross margin of -100.00% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Waverley Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Waverley Pharma (TSXV:WAVE) Business Description

Traded in Other Exchanges
Address
1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Executives
Albert David Friesen 10% Security Holder, Director, Senior Officer

Waverley Pharma (TSXV:WAVE) Headlines

From GuruFocus